Nurix Therapeutics, INC. (NRIX) — SEC Filings

Q: What are the key financial highlights for Nurix Therapeutics, INC.?

Key financial highlights for Nurix Therapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Nurix Therapeutics, INC.?

Key executives at Nurix Therapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Nurix Therapeutics, INC. stock?

Risk factors for Nurix Therapeutics, INC. (NRIX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Nurix Therapeutics, INC.?

Forward-looking statements and predictions from Nurix Therapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Nurix Therapeutics, INC.. Recent 10-Q filing on Apr 8, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Nurix Therapeutics, INC. on SEC EDGAR

Overview

Nurix Therapeutics, INC. (NRIX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Apr 8, 2026: Nurix Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending February 28, 2026. The filing includes financial statements and disclosures required for public companies. The company's mailing and business address is 1600 Sierra Point Parkway, Brisbane, CA 94005.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 5 bullish, 1 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Nurix Therapeutics, INC. is neutral.

Filing Type Overview

Nurix Therapeutics, INC. (NRIX) has filed 7 10-Q, 21 8-K, 1 ARS, 1 DEFA14A, 2 DEF 14A, 2 10-K, 11 SC 13G/A, 5 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

Nurix Therapeutics Files Q1 2026 10-Q Report — 10-Q · Apr 8, 2026 Risk: low
Nurix Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending February 28, 2026. The filing includes financial statements and disclosur
8-K Filing — 8-K · Apr 8, 2026
Nurix Therapeutics Files Annual Report — ARS · Mar 27, 2026 Risk: low
Nurix Therapeutics, Inc. filed an Annual Report to Security Holders (ARS) on March 27, 2026, for the period ending November 30, 2025. The company, headquartered
Nurix Therapeutics Files Proxy Materials — DEFA14A · Mar 27, 2026 Risk: low
Nurix Therapeutics, Inc. filed a DEFA14A form on March 27, 2026, related to additional definitive proxy soliciting materials. The filing includes various docume
8-K Filing — 8-K · Dec 9, 2025
8-K Filing — 8-K · Nov 10, 2025
Nurix Therapeutics Files 8-K — 8-K · Oct 22, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on October 22, 2025, reporting other events and financial statements. The filing does not contain specific details about n
Nurix Therapeutics Files 8-K — 8-K · Oct 22, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on October 22, 2025, reporting on other events and financial statements. The filing does not contain specific details abou
Nurix's Losses Widen to $186M Amid Soaring R&D Costs — 10-Q · Oct 9, 2025 Risk: high
Nurix Therapeutics, Inc. reported a significant increase in net loss for the nine months ended August 31, 2025, reaching $(186.2) million, up from $(135.0) mill
Nurix Therapeutics Files 8-K — 8-K · Sep 3, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on September 3, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
Nurix Therapeutics Names New CEO, Restructures Leadership — 8-K · Aug 22, 2025 Risk: medium
Nurix Therapeutics, Inc. announced on August 19, 2025, changes in its executive and board leadership. Dr. G. Jonah Wilson has been appointed as the new Chief Ex
Nurix Collaboration Revenue Jumps 38% in Q2 — 10-Q · Jul 9, 2025 Risk: medium
Nurix Therapeutics, Inc. reported collaboration revenue of $10.9 million for the three months ended May 31, 2025, a significant increase from $7.9 million for t
Nurix Therapeutics Files 8-K — 8-K · Jun 12, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exh
Nurix Therapeutics Files 8-K on Shareholder Votes & Exhibits — 8-K · May 19, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The filin
Nurix Therapeutics Files Q1 2025 10-Q — 10-Q · Apr 8, 2025 Risk: medium
Nurix Therapeutics, Inc. filed a 10-Q for the period ending February 28, 2025. The filing covers the first quarter of their fiscal year. Key financial data and
Nurix Therapeutics Files 2025 Proxy Statement — DEF 14A · Mar 28, 2025 Risk: low
Nurix Therapeutics, Inc. filed its definitive proxy statement on March 28, 2025, for its annual meeting of stockholders scheduled for May 19, 2025. The filing o
Nurix Therapeutics Appoints New CMO, Director — 8-K · Mar 13, 2025 Risk: low
Nurix Therapeutics, Inc. announced on March 11, 2025, the appointment of Dr. Robert L. Kirk as Chief Medical Officer and the election of Ms. Jennifer L. Jones t
Nurix Therapeutics Files 2024 Annual Report — 10-K · Jan 28, 2025 Risk: low
Nurix Therapeutics, Inc. filed its annual report for the fiscal year ended November 30, 2024. The company is a well-known seasoned issuer and is registered with
Nurix Therapeutics Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation F
Sanofi to Acquire Nurix Therapeutics for $2.4 Billion — 8-K · Dec 10, 2024 Risk: medium
Nurix Therapeutics, Inc. announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Sanofi for approximately $2.4 billion.
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 8, 2024
SC 13G/A Filing — SC 13G/A · Nov 7, 2024
Nurix Therapeutics Files 8-K — 8-K · Oct 31, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on October 31, 2024, reporting other events and financial statements. The filing does not contain specific financial figur
Nurix Therapeutics Appoints New CMO, Adds Director — 8-K · Oct 16, 2024 Risk: medium
Nurix Therapeutics, Inc. announced on October 15, 2024, the appointment of Dr. Robert L. Kirk as Chief Medical Officer and the election of Ms. Jennifer L. D. Go
Nurix Therapeutics Q3 Revenue Rises — 10-Q · Oct 11, 2024 Risk: medium
Nurix Therapeutics, Inc. filed its 10-Q for the period ending August 31, 2024. The company reported collaboration revenue of $12.5 million for the three months
Nurix Therapeutics Files 8-K Disclosure Update — 8-K · Sep 5, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on September 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
Nurix Therapeutics Q2 Revenue Declines — 10-Q · Jul 11, 2024 Risk: medium
Nurix Therapeutics, Inc. filed its 10-Q for the period ending May 31, 2024. The company reported collaboration revenue of $10.1 million for the three months end
Sanofi to Acquire Nurix Therapeutics for $2.3 Billion — 8-K · Jun 17, 2024 Risk: medium
Nurix Therapeutics, Inc. announced on June 16, 2024, that it has entered into a definitive agreement to be acquired by Sanofi for approximately $2.3 billion. Th
SC 13G/A Filing — SC 13G/A · Jun 7, 2024
Nurix Therapeutics Files 8-K on Shareholder Votes and Financials — 8-K · May 21, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on May 20, 2024, to report on the submission of matters to a vote of security holders and financial statements. The filing
Nurix Therapeutics Announces Material Definitive Agreement — 8-K · Apr 12, 2024 Risk: medium
On April 11, 2024, Nurix Therapeutics, Inc. announced a material definitive agreement, indicating a significant development for the company. The filing also inc
Nurix Therapeutics, Inc. Files 10-Q for Period Ending February 29, 2024 — 10-Q · Apr 10, 2024 Risk: low
Nurix Therapeutics, Inc. (NRIX) filed a Quarterly Report (10-Q) with the SEC on April 10, 2024. Nurix Therapeutics, Inc. filed a 10-Q for the period ending Febr
Nurix Therapeutics Files 8-K — 8-K · Apr 9, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on April 9, 2024, reporting other events and financial statements. The filing details the company's principal executive of
Nurix Therapeutics Announces 2024 Annual Meeting of Stockholders — DEF 14A · Mar 27, 2024 Risk: low
Nurix Therapeutics, Inc. (NRIX) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. The 2024 Annual Meeting of Stockholders for Nurix Therapeutics
Nurix Therapeutics Files 8-K — 8-K · Mar 11, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on March 11, 2024, to report other events and financial statements. The filing does not contain specific details about new
Nurix Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Feb 15, 2024 Risk: medium
Nurix Therapeutics, Inc. (NRIX) filed a Annual Report (10-K) with the SEC on February 15, 2024. Nurix Therapeutics, Inc. filed its 2023 Form 10-K on February 15
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 13, 2024
Morgan Stanley Discloses 5.0% Stake in Nurix Therapeutics (NRIX) — SC 13G · Feb 9, 2024 Risk: low
Morgan Stanley, a major financial institution, filed an SC 13G on February 9, 2024, disclosing that as of December 31, 2023, it beneficially owns 3,000,000 shar
Wasatch Advisors Maintains 5.7% Stake in Nurix Therapeutics — SC 13G/A · Feb 9, 2024 Risk: low
Wasatch Advisors LP, an investment adviser, filed an amended SC 13G/A on February 9, 2024, indicating a change in its ownership of Nurix Therapeutics, Inc. comm
ARK Investment Management Discloses 3.2M Share Stake in Nurix Therapeutics — SC 13G · Jan 29, 2024
ARK Investment Management LLC, a prominent investment firm, reported on January 29, 2024, that it beneficially owns 3,194,999 shares of Nurix Therapeutics, Inc.
BlackRock Amends Nurix Therapeutics Stake as of Dec 31, 2023 — SC 13G/A · Jan 24, 2024
BlackRock Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating a change in its ownership of Nurix Therapeutics, Inc. common stock as of December
State Street Corp. Updates Passive Stake in Nurix Therapeutics — SC 13G/A · Jan 23, 2024
State Street Corporation, a major financial institution, filed an amended Schedule 13G/A on January 23, 2024, indicating its ownership of Nurix Therapeutics, In
Nurix Therapeutics Files 8-K for Regulatory Disclosure & Exhibits — 8-K · Jan 8, 2024
Nurix Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits

Risk Profile

Risk Assessment: Of NRIX's 32 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Nurix Therapeutics, INC.'s most recent 10-Q filing (Oct 9, 2025):

Revenue: $70,403,000
Net Income: $(186,236,000)
EPS: $(2.22)
Debt-to-Equity: 0.40
Cash Position: $428,829,000
Operating Margin: -287.8%
Total Assets: $522,472,000
Total Debt: $150,220,000

Key Executives

G. Jonah Wilson
Arthur T. Sands
Jennifer L. D. Fox
Dr. Robert L. Kirk
Ms. Jennifer L. Jones
Ms. Jennifer L. D. Good
December 31, 2023

Industry Context

The biopharmaceutical industry, particularly in the oncology and immunology space where Nurix operates, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Nurix rely heavily on innovation and the successful progression of drug candidates through clinical trials. The competitive landscape is intense, with many players vying for market share and significant investment from venture capital and public markets.

Top Tags

biotech (9) · sec-filing (6) · 10-Q (5) · institutional-ownership (5) · corporate-governance (4) · 8-k (3) · 8-K (3) · Biotechnology (3) · Nurix Therapeutics (3) · amendment (3)

Key Numbers

iXBRL 10-Q Size: 1346546 — Size of the main 10-Q filing document in bytes.
Complete submission text file Size: 6121370 — Size of the complete submission text file in bytes.
Fiscal Year End: 2025-11-30 — The reporting period for the ARS filing.
Filing Date: 2026-03-27 — The date the ARS was officially filed with the SEC.
DEFA14A Document Size: 16915 — Size of the primary DEFA14A filing in KB.
GRAPHIC Document Size: 403947 — Size of the first graphic file in bytes.
Net Loss: $(186.2)M — Increased from $(135.0)M in 2024 for the nine months ended August 31, 2025
Research and Development Expenses: $233.9M — Increased from $154.4M in 2024 for the nine months ended August 31, 2025
Total Revenue: $70.4M — Increased from $41.3M in 2024 for the nine months ended August 31, 2025, driven by license revenue
License Revenue: $30.0M — Recognized for the nine months ended August 31, 2025, contributing to revenue growth
Net Cash Used in Operating Activities: $(181.6)M — For the nine months ended August 31, 2025, indicating significant cash burn
Cash, Cash Equivalents and Marketable Securities: $428.8M — Decreased from $609.6M as of November 30, 2024, to August 31, 2025
Shares of Common Stock Outstanding: 76,883,436 — As of September 30, 2025
Net Loss Per Share (3 months): $(1.03) — Increased from $(0.67) in the prior year quarter
Net Loss Per Share (9 months): $(2.22) — Increased from $(2.13) in the prior year period

Forward-Looking Statements

{"claim":"Nurix Therapeutics' stock price may see increased stability or upward pressure due to institutional interest.","entity":"Nurix Therapeutics, Inc.","targetDate":"next 3-6 months","confidence":"medium"}
{"claim":"Wasatch Advisors LP will maintain its significant stake in Nurix Therapeutics, Inc. for the foreseeable future.","entity":"Wasatch Advisors LP","targetDate":"2025-02-09","confidence":"medium"}

Related Companies

GILD · SNY · PFE

Frequently Asked Questions

What are the latest SEC filings for Nurix Therapeutics, INC. (NRIX)?

Nurix Therapeutics, INC. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 21 8-K, 11 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of NRIX filings?

Across 50 filings, the sentiment breakdown is: 5 bullish, 1 bearish, 43 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Nurix Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Nurix Therapeutics, INC. (NRIX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Nurix Therapeutics, INC.?

Key financial highlights from Nurix Therapeutics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for NRIX?

The investment thesis for NRIX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Nurix Therapeutics, INC.?

Key executives identified across Nurix Therapeutics, INC.'s filings include G. Jonah Wilson, Arthur T. Sands, Jennifer L. D. Fox, Dr. Robert L. Kirk, Ms. Jennifer L. Jones and 2 others.

What are the main risk factors for Nurix Therapeutics, INC. stock?

Of NRIX's 32 assessed filings, 1 were flagged high-risk, 10 medium-risk, and 21 low-risk.

What are recent predictions and forward guidance from Nurix Therapeutics, INC.?

Recent forward-looking statements from Nurix Therapeutics, INC. include guidance on {"claim":"Nurix Therapeutics' stock price may see increased stability or upward pressure due to institutional interest." and 1 other predictions.